Press Releases
Press Releases
| 5/18/2010 |
Cempra Pharmaceutical's Cem-101 Demonstrates Potent Anti-Inflammatory Activity, Compared To Other Macrolide Antibiotics, In An Inflammation Cell Model At The American Thoracic Society 2010 International Conference Cempra Pharmaceuticals today announced the results from two poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, at the American Thoracic Society 2010 International Conference, May 14 to 19, 2010, in New Orleans... |
| 5/6/2010 |
Cempra Pharmaceuticals Names Mark W. Hahn as Executive Vice President and Chief Financial Officer Cempra Pharmaceuticals Inc. today announced the appointment of Mark W. Hahn as executive vice president and chief financial officer... |
| 5/4/2010 |
Cempra Announces Positive Results From Its Phase 2 Clinical Trial Of Takstatm (Sodium Fusidate) In Patients With Acute Bacterial Skin And Skin Structure Infections (Absssi) Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA™ (CEM-102, sodium fusidate), the company’s oral, anti-methicillinresistant Staphylococcus aureus (MRSA) antibiotic. The study demonstrated efficacy... |
| 4/10/2010 |
Cempra pharmaceuticals presents new data on its multi-drug resistant anti-infective portfolio, cem-101 and takstatm (cem-102), at the 20th european congress of clinical microbiology and infectious disease Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102 (TAKSTA), the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology... |
| 4/8/2010 |
Cempra pharmaceuticals will present new data on cem-101 and takstatm (cem-102) at the 20th european congress of clinical microbiology and infectious disease Cempra Pharmaceuticals today announced its schedule of poster presentations at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, on April 10-13, 2010.... |
| 4/6/2010 |
Cempra announces expansion of clinical management team to advance leading antibacterial clinical programs takstatm and cem-101 Cempra Pharmaceuticals today announced the expansion of its clinical development team to manage the company's leading clinical programs, CEM-101 and TAKSTA (formerly CEM-102) through advanced clinical development. The four appointments, including Susan R. Moriarty, M.D. and Jennifer .... |
| 3/10/2010 |
Cempra announces The Completion of Phase 1 Studies for cem-101, a next-generation macrolide Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study.... |
| 3/4/2010 |
Cempra Pharmaceuticals To Present At The Cowen And Company 30th Annual Health Care Conference Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Cowen and Company 30th Annual Health Care Conference at 3 p.m. EST, March 8, 2010, at The Boston Marriott Copley Place in Boston... |
| 1/19/2010 |
Cempra Completes Enrollment Of Phase 2 Portion Of Phase 2/3 Clinical Trial Of Takstatm (Cem-102 Or Sodium Fusidate) For Treatment Of Acute Bacterial Skin And Structure Infections Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA... |
| 1/8/2010 |
Cempra Pharmaceuticals Names Donald C. Olsen Executive Vice President Of Business Development Cempra Pharmaceuticals Inc. today announced the appointment of Donald C. Olsen as executive vice president of business development. Mr. Olsen will oversee the... |
| 11/25/2009 |
Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Piper Jaffray 21st Annual Health Care Conference... |
| 11/13/2009 |
Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will... |
| 10/29/2009 |
Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America... |
| 10/29/2009 |
Presentations of Cempra Pharmaceutical's CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate Cempra Pharmaceuticals today announced data presentations of its lead antibiotic candidate, CEM-102 (fusidic acid)... |
| 10/22/2009 |
Cempra Pharmaceuticals Will Present New Data on CEM-101 and CEM-102 at the Infectious Disease Society Of America, 47th Annual Meeting Cempra Pharmaceuticals today announced its schedule of oral and poster presentations at the Infectious Disease Society of America... |
| 09/09/2009 |
Cempra Pharmaceuticals Initiates Phase 2/3 Clinical Study for an Oral Antibiotic to Treat Acute Bacterial Skin Structure Infections Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering... |
| 08/12/2009 |
Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors Cempra Pharmaceuticals today announced the appointment of John H. Johnson, Chief Executive Officer of ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to the company’s Board of Directors... |
| 05/14/2009 |
Cempra Pharmaceuticals Closes $46M Series C Financing Funds will advance clinical development of two lead antibiotic compounds and the company's pre-clinical pipeline... |
| 04/28/2009 |
Cempra Pharmaceuticals Inc. announces lead macrolide is active in vitro against clinically significant antibiotic-resistant pathogenic organisms Cempra Pharmaceuticals today announced the publication of new research in the May issue of Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology, demonstrating that its lead compound, CEM-101 ... |
| 09/30/2008 |
Cempra Pharmaceuticals and Biovista Enter Agreement For Macrolide Clinical Trial Design Support Studies Cempra Pharmaceuticals, Inc., and Biovista, Inc., announced today that they have entered into a research agreement to systematically identify and profile adverse event associations for members of the macrolide drug class ... |
| 10/03/2006 |
Aisling Capital Joins I. Wistar Morris III and Intersouth Partners as a Lead Investor in Cempra Pharmaceuticals Anti-infective biotechnology company Cempra Pharmaceuticals announced today that it has added Aisling Capital as an investor ... |
| 08/16/2006 |
Cempra Pharmaceuticals Raises $14 Million Round of Financing Cempra Pharmaceuticals, a biotechnology company developing anti-infective medicines ... |
| 04/04/2006 |
Cempra Pharmaceuticals Receives Exclusive Rights from Optimer Pharmaceuticals for Its Macrolide Antibacterial Program Cempra Pharmaceuticals, Inc. announced that Optimer Pharmaceuticals has granted to Cempra exclusive worldwide rights (except ASEAN countries ... |